Symposium to Spotlight Advancements in Translational Cancer Research
Columbia University to co-host Feb. 7-8 Cancer Genomics and Mathematical Data Analysis Symposium with Cornell University and Memorial Sloan Kettering
A multidisciplinary team of researchers across Columbia University have been busy addressing the complex challenges in basic and translational cancer research. Faculty and investigators are bridging their expertise in fields ranging from mathematics, biology, and engineering to physics, genomics, and chemistry to develop innovative approaches to better understand, for instance, cancer disease progression, drug resistance, and the systems-wide network of tumor evolution.
Central to this ongoing work is research grounded in cancer genomics and mathematical data analysis, which will be explored during a two-day conference Feb. 7-8 co-hosted by the National Cancer Institute (NCI) centers at Columbia University Medical Center, Cornell University, and Memorial Sloan Kettering Cancer Center. The upcoming Cancer Genomics and Mathematical Data Analysis Symposium will be held at the Vivian and Seymour Milstein Family Heart Conference Center; pre-registration is required
"Genomics is becoming an important tool for the quantitative study of biological systems,” says Raul Rabadan, PhD, professor of systems biology at Columbia and director of the Center for Topology of Cancer Evolution and Heterogeneity and of the Program for Mathematical Genomics. “This meeting organized by four different NCI centers addresses some of the important challenges and new perspectives on the quantitative understanding of cancer using genomics tools.”
Expected guest speakers include leading computational biologists, physicists, engineers, mathematicians, and oncologists, who are slated to deliver talks on topics, such as cancer precision medicine, the evolutionary dynamics of cancer and response to treatment, cancer heterogeneity, and identifying cancer vulnerabilities on an individual cell basis. Day one of the conference will wrap with a networking social and poster session—open to students and post-doctoral scientists—with prizes sponsored by Cancer Reports, a new journal for cancer research published by Wiley.
The Center for Topology of Cancer Evolution and Heterogeneity at Columbia, co-directed by Drs. Rabadan and Antonio Iavarone, professor of pathology and cell biology and of neurology at Columbia, represents NCI’s Physical Sciences in Oncology Network (PSOC). The interdisciplinary center, which includes experts in cancer genomics, developmental biology, single-cell genomics, machine learning, and topological data analysis, are working to develop and validate a set of complementary approaches that will provide the cancer research community with a framework for unraveling tumor complexity.
Andrea Califano, Dr., chair of Columbia’s Department of Systems Biology, and Barry Honig, PhD, professor of systems biology and of biochemistry and molecular biophysics at Columbia, who will both deliver talks at the symposium, co-direct the NCI’s Cancer Systems Biology Consortium at Columbia, the Center for Cancer Systems Therapeutics (CaST). CaST, which is comprised of faculty from several departments and institutes across Columbia, focuses on the use of experimental biology combined with multi-dimensional data analysis and systems engineering in its approach to tackling challenges in translational cancer research. CaST investigators are experts in the development of computational methods for analyzing functional and structural data, high-throughput technologies for single-cell profiling, high-throughput genetic and pharmacological screening, software development, and experimental methods for studying tumor evolution in vivo.
The two additional NCI centers co-hosting the symposium include the Cornell Center on the Physics of Cancer Metabolism, co-directed by Drs. Claudia Fischbach-Teschl and Lewis C. Cantley, and Memorial Sloan Kettering’s Center for Cancer Systems Immunology, led by Drs. Christina Leslie and Alexander Rudensky. The interdisciplinary team at MSK’s Center for Cancer Systems Immunology is conducting research in the areas of immunotherapy, gene regulation, cancer genetics, and metastasis. At Cornell’s Center on the Physics of Cancer Metabolism, researchers are zeroing in on multiscale biophysical mechanisms regulating tumor metabolism and function and their consequences on clinical outcome.
A highlight of the symposium also will be a discussion lead by data science-biomedical research nonprofit Sage Bionetworks on the DREAM challenges. DREAM, or Dialogue for Reverse Engineering Assessment and Methods, was established by IBM Researcher Gustavo Stolovitzky and Dr. Califano as a worldwide crowdsourcing effort posing quantitative challenges centered on biomedical modeling and data analysis. To date, DREAM has organized 45 challenges, engaging more than 20,000 scientists from universities, industry, and the private sector, resulting in over 100 publications. The idea behind DREAM is to catalyze translational discoveries that truly impact human health through the power of crowdsourcing competitions.
The Feb. 7-8 symposium at Columbia also welcomes speakers from Anderson Cancer Center, Cambridge Institute, Cornell, Duke University, Memorial Sloan Kettering, University of Texas-Austin, and the University of Washington.
For further details and to register for the event, visit the symposium page.